Tim Heise, MD is an expert in Endocrinology at Profil Institute for Metabolic Research (Germany). As of October 2026, ScienceLeadR ranks Tim Heise in the top 1% of experts worldwide for Diabetes Mellitus and Glucose Metabolism Disorders. Tim Heise has authored 321 publications, the most recent in 2026, and is an investigator in 32 clinical trials. SLR score: 1,215 (community average: 125). How the SLR is computed.

LeadR Profile

1 215 ScienceLeadR Reputation 1215
Network Map

Endocrinology

Subspecialties: Pharmacy - Cardiology - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Dr Heise is Chief Scientific Officer and Chairman of the Board of Directors of the private research institute Profil in Neuss, Germany. Founded in 1999 by Dr Heise and Dr Lutz Heinemann, Profil became known as the premier source of solutions to the challenging early phase studies of experimental diabetes and obesity treatments often using sophisticated methodology like the glucose clamp technique in combination with isotope dilution, biopsies and/or indirect calorimetry.

Dr Heise has led numerous studies in people with type 1 or type 2 diabetes, obesity, pre-diabetes and insulin resistance. His research focus is the pharmacological properties of antidiabetic and weight-loss drugs, in particular novel insulin preparations and incretin-based therapies. In addition, his study team at Profil has gained outstanding reputation for the evaluation of medical devices.

Before establishing Profil, Dr Heise worked for more than 7 years at the Clinic for Nutrition and Metabolic Diseases at the Heinrich-Heine-University Düsseldorf (Head Prof Michael Berger). During this time, he was responsible for the diabetes and obesity outpatient clinics and took care of patients in structured teaching and treatment programs for type 1 and type 2 diabetes.

Dr Heise has published more than 250 scientific papers and reviews. He is a member of the Editorial Boards of Diabetes, Obesity and Metabolism, and Diabetes Technology & Therapeutics.

Organizations

Career arc: 1994 - 2026

Source: PubMed

Profil Institute for Metabolic Research

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 321

Citations

Citations: 16 792 1st author: 85 Last author: 55 Unique author: 8


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.
PMID 42229460 — diabetes mellitus, glucagon-like peptide 1, cells, insulin, insulin secretion, drug-related side effects and adverse reactions, therapeutics, diabetes mellitus, type 2
Diabetes Obes Metab20260
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.
PMID 42017294 — safety, anti-obesity agents, therapeutics, overweight, pharmacokinetics, weight control
Diabetes Obes Metab20260
Personal Viewpoint: Risk stratification and counseling of living kidney donor candidates with prediabetes.
PMID 41759934 — diabetes mellitus, hemoglobins, fasting, glucose tolerance test, homeostasis, kidney, prediabetic state, counseling, transplantation
Am J Transplant20260
Characterisation of steady-state pharmacokinetics and glucodynamics of once-weekly insulin efsitora alfa in individuals with type 2 diabetes.
PMID 41725424 — diabetes mellitus, insulin, pharmacokinetics, diabetes mellitus, type 2
Diabetes Obes Metab20260
Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).
PMID 40884070 — mortality, heart failure, heart, neoplasms, self care, cardiology, therapeutics, palliative care
Eur Heart J Top journal202510

Clinical Studies 32

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 1 19
Phase 2 8
Phase 1/Phase 2 3
N/A 2

By status:

Completed 28
Terminated 3
Suspended 1

By type:

Interventional 32

By Monocentric/Multicentric:

monocentric 20
multicentric2to4 6
multicentric5to9 2
multicentricup10 4

Main Topics

LeadR Networks

Main global connection map